WO2023285677 - PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
National phase entry is expected:
Publication Number
WO/2023/285677
Publication Date
19.01.2023
International Application No.
PCT/EP2022/069908
International Filing Date
15.07.2022
Title **
[English]
PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
[French]
COMBINAISONS PHARMACEUTIQUES POUR LE TRAITEMENT DU CANCER
Applicants **
SPEXIS AG
Hegenheimermattweg 125
4123 Allschwil, CH
Inventors
ZIMMERMANN, Johann
Königsbergerstrasse 9
79379 Müllheim, DE
BERTONI, Francesco
Via Belsoggiorno 20
6500 Bellinzona, CH
ARRIBAS CARMENA, Jesus Alberto
Piazzale Marconi 35
21016 Luino, IT
Priority Data
21020370.9
16.07.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1756 | |
| EPO | Filing, Examination | 8287 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3110 |
Total: 14319 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to pharmaceutical combinations comprising a peptidic CXCR4 inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor for use in a method for the prevention, delay of progression or treatment of cancer.[French]
La présente invention concerne des combinaisons pharmaceutiques comprenant un inhibiteur de CXCR4 peptidique et un inhibiteur de la tyrosine kinase de Bruton (BTK) pour une utilisation dans un procédé pour la prévention, le retardement de la progression ou le traitement du cancer.